|
|
Article: Abilify Has Made Strong Gains in Patient Share Across All Lines of Therapy Since Last Year's Analysis of Prescribing Trends in Schizophrenia.
- Article from:
- PR Newswire
- Article date:
- July 23, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Surveyed Psychiatrists Will Remain Focused on Agents' Metabolic Side Effects When Treating Patients, According to a New Report from Decision Resources Patient-Flow Forecasts Need to Take Into Account Invega's Shift Towards Use in Earlier Lines of Therapy Over the Next Two Years
WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. Abilify is second to ...